PMID- 35737449 OWN - NLM STAT- MEDLINE DCOM- 20220627 LR - 20220823 IS - 1438-8871 (Electronic) IS - 1439-4456 (Print) IS - 1438-8871 (Linking) VI - 24 IP - 6 DP - 2022 Jun 23 TI - Medication Use and Clinical Outcomes by the Dutch Institute for Clinical Auditing Medicines Program: Quantitative Analysis. PG - e33446 LID - 10.2196/33446 [doi] LID - e33446 AB - BACKGROUND: The Dutch Institute for Clinical Auditing (DICA) Medicines Program was set up in September 2018 to evaluate expensive medicine use in daily practice in terms of real-world effectiveness using only existing data sources. OBJECTIVE: The aim of this study is to describe the potential of the addition of declaration data to quality registries to provide participating centers with benchmark information about the use of medicines and outcomes among patients. METHODS: A total of 3 national population-based registries were linked to clinical and financial data from the hospital pharmacy, the Dutch diagnosis treatment combinations information system including in-hospital activities, and survival data from health care insurers. The first results of the real-world data (RWD) linkage are presented using descriptive statistics to assess patient, tumor, and treatment characteristics. Time-to-next-treatment (TTNT) and overall survival (OS) were estimated using the Kaplan-Meier method. RESULTS: A total of 21 Dutch hospitals participated in the DICA Medicines Program, which included 7412 patients with colorectal cancer, 1981 patients with metastasized colon cancer, 3860 patients with lung cancer, 1253 patients with metastasized breast cancer, and 7564 patients with rheumatic disease. The data were used for hospital benchmarking to gain insights into medication use in specific patient populations, treatment information, clinical outcomes, and costs. Detailed treatment information (duration and treatment steps) led to insights into differences between hospitals in daily clinical practices. Furthermore, exploratory analyses on clinical outcomes (TTNT and OS) were possible. CONCLUSIONS: The DICA Medicines Program shows that it is possible to gather and link RWD about medicines to 4 disease-specific population-based registries. Since these RWD became available with minimal registration burden and effort for hospitals, this method can be explored in other population-based registries to evaluate real-world efficacy. CI - (c)Rawa Kamaran Ismail, Jesper van Breeschoten, Silvia van der Flier, Caspar van Loosen, Anna Maria Gerdina Pasmooij, Maaike van Dartel, Alfons van den Eertwegh, Anthonius de Boer, Michel Wouters, Doranne Hilarius. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 23.06.2022. FAU - Ismail, Rawa Kamaran AU - Ismail RK AUID- ORCID: 0000-0002-0838-0349 AD - Division of Pharmacoepidemiology and Clinical Pharmacology, University of Utrecht, Utrecht, Netherlands. FAU - van Breeschoten, Jesper AU - van Breeschoten J AUID- ORCID: 0000-0002-1334-2232 AD - Dutch Institute for Clinical Auditing, Leiden, Netherlands. FAU - van der Flier, Silvia AU - van der Flier S AUID- ORCID: 0000-0002-5427-7289 AD - Stichting Volksgezondheidszorg (VGZ), Arnhem, Netherlands. FAU - van Loosen, Caspar AU - van Loosen C AUID- ORCID: 0000-0002-4461-806X AD - Dutch Association of Hospital Pharmacists, De Meern, Netherlands. FAU - Pasmooij, Anna Maria Gerdina AU - Pasmooij AMG AUID- ORCID: 0000-0003-0641-3829 AD - Medicines Evaluation Board, Utrecht, Netherlands. FAU - van Dartel, Maaike AU - van Dartel M AUID- ORCID: 0000-0002-1234-1465 AD - Medicines Evaluation Board, Utrecht, Netherlands. FAU - van den Eertwegh, Alfons AU - van den Eertwegh A AUID- ORCID: 0000-0003-2196-1233 AD - Department of Medical Oncology, Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands. FAU - de Boer, Anthonius AU - de Boer A AUID- ORCID: 0000-0002-9485-8037 AD - Division of Pharmacoepidemiology and Clinical Pharmacology, University of Utrecht, Utrecht, Netherlands. FAU - Wouters, Michel AU - Wouters M AUID- ORCID: 0000-0001-6173-0662 AD - Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, Netherlands. FAU - Hilarius, Doranne AU - Hilarius D AUID- ORCID: 0000-0001-6638-9467 AD - Rode Kruis Ziekenhuis, Beverwijk, Netherlands. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220623 PL - Canada TA - J Med Internet Res JT - Journal of medical Internet research JID - 100959882 SB - IM MH - Benchmarking MH - Health Services MH - Hospitals MH - Humans MH - *Neoplasms/drug therapy MH - Registries PMC - PMC9264125 OTO - NOTNLM OT - cancer OT - medicines OT - quality of care OT - real-world data COIS- Conflicts of Interest: AE has advisory relationships with Amgen Inc, Bristol Myers Squibb, F. Hoffmann-La Roche AG, Novartis International AG, MSD, Laboratoires Pierre Fabre, Sanofi SA, Pfizer Inc, Ipsen SA, and Merck & Co Inc, and has received research grants not related to this paper from Sanofi SA, F. Hoffmann-La Roche AG, Bristol Myers Squibb, Idera Inc, and Teva Pharmaceutical Industries Ltd. AE has received travel expenses from MSD Oncology, F. Hoffmann-La Roche AG, Pfizer Inc, and Sanofi SA, and has received speaker honoraria from Bristol Myers Squibb and Novartis International AG. All other authors declare no conflicts of interest. EDAT- 2022/06/24 06:00 MHDA- 2022/06/28 06:00 PMCR- 2022/06/23 CRDT- 2022/06/23 11:53 PHST- 2021/09/29 00:00 [received] PHST- 2022/04/30 00:00 [accepted] PHST- 2022/04/06 00:00 [revised] PHST- 2022/06/23 11:53 [entrez] PHST- 2022/06/24 06:00 [pubmed] PHST- 2022/06/28 06:00 [medline] PHST- 2022/06/23 00:00 [pmc-release] AID - v24i6e33446 [pii] AID - 10.2196/33446 [doi] PST - epublish SO - J Med Internet Res. 2022 Jun 23;24(6):e33446. doi: 10.2196/33446.